Genetic signatures

Genetic Signatures: Revolutionizing Pathogen Detection with EasyScreen Kits

Genetic Signatures is a leading molecular diagnostics company that specializes in developing and commercializing innovative pathogen detection solutions. The company's flagship product, the EasyScreen pathogen detection kit, has revolutionized the way hospitals and pathology laboratories screen for infectious pathogens.

With traditional methods of pathogen detection being time-consuming and labor-intensive, Genetic Signatures recognized the need for a faster and more efficient solution. The EasyScreen kit provides a rapid high-throughput environment that enables laboratories to screen for a wide array of infectious pathogens in just hours instead of days.

The technology behind the EasyScreen kit is based on proprietary 3base™ technology, which allows for highly specific and sensitive detection of target DNA sequences. This means that even low levels of pathogens can be detected accurately, reducing false negatives and improving patient outcomes.

The EasyScreen kit is also incredibly versatile, with over 300 different assays available to detect various bacterial, viral, fungal, and parasitic infections. This makes it an essential tool for hospitals and pathology laboratories worldwide as they strive to combat emerging infectious diseases.

In addition to its groundbreaking technology, Genetic Signatures has also made significant strides in expanding its global reach through strategic partnerships with key distributors across Europe, Asia-Pacific region including China & Japan , Middle East & Africa (MEA), Latin America (LATAM) & North America (NA). These partnerships have enabled the company to bring its innovative solutions to new markets while maintaining high standards of quality control.

One notable milestone in Genetic Signatures' journey was its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) in 2015. The IPO raised AUD 25 million ($18 million USD), which allowed the company to accelerate its growth plans by investing in research & development activities as well as expanding sales channels globally.

Since then Genetic Signatures has continued to grow from strength-to-strength by launching new products such as Clinical Validation Kits which are designed specifically for clinical trials or validation studies; this product line helps researchers validate their assays quickly without having access expensive equipment or expertise required otherwise .

In conclusion , Genetic signatures' commitment towards innovation coupled with their focus on quality control has made them one of the most trusted names when it comes to molecular diagnostics . With their cutting-edge technology like 3base™ , versatile assay menu , global distribution network & strong financial position thanks largely due successful IPO listing on ASX ; they are poised continue making significant contributions towards improving patient outcomes worldwide .